On June 15, 2021 Acorda Therapeutics, Inc. (Nasdaq: ACOR) reported that on June 15, 2021, it repaid in full its 1.75% Convertible Senior Notes due 2021(Press release, Acorda Therapeutics, JUN 16, 2021, View Source [SID1234584039]). Prior to their maturity and repayment, there were $69.0 million aggregate principal amount of 2021 notes outstanding. The 2021 notes were repaid using cash on hand.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The repayment of the 2021 notes removes an overhang on the company and is another important milestone in our strategy, following the sale of our manufacturing operations earlier this year. We are focused on accelerating the growth of INBRIJA, continuing to maintain the strength of AMPYRA, and optimizing the company’s financial structure," said Ron Cohen, M.D., Acorda’s President and Chief Executive Officer. "We have maintained cost discipline since our restructuring announcement in February and are continuing to drive toward cash flow breakeven.